| アブストラクト | Hemophagocytic lymphohistiocytosis (HLH) has been reported rarely with BRAF/MEK inhibitor combinations, including dabrafenib/trametinib. Postmarketing pharmacovigilance analyses evaluating outcomes associated with dabrafenib/trametinib-induced HLH are also lacking. Herein, we report a case of dabrafenib/trametinib-induced HLH in a patient with metastatic melanoma. Recovery of HLH-related symptoms was observed following drug discontinuation, supportive care, and corticosteroids. We also conducted a pharmacovigilance analysis of the USA Food and Drug Administration Adverse Event Reporting System (FAERS) to describe postmarketing cases of HLH with dabrafenib/trametinib exposure. There were 50 reports of HLH with dabrafenib/trametinib in FAERS. Most cases occurred in the setting of melanoma ( n = 39; 78%) and most were reported in Europe ( n = 39; 74%). Hospitalization was the most common outcome ( n = 39; 78%) of this adverse event per FAERS. HLH is a rare complication of dabrafenib/trametinib, and clinicians should be aware and monitor for signs of this potentially serious and life-threatening adverse event. |
|---|
| ジャーナル名 | Melanoma research |
|---|
| Pubmed追加日 | 2024/7/22 |
|---|
| 投稿者 | Elmes, Joseph B; Davis, Jessica M; Musselwhite, Laura W; Chiad, Zane; Moore, Donald C; Amin, Asim |
|---|
| 組織名 | Department of Pharmacy, Atrium Health Levine Cancer, Concord.;Department of Pharmacy, Atrium Health Levine Cancer, Charlotte, Departments of.;Solid Tumor Oncology.;Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer, Concord.;Department of Solid Tumor Oncology, Atrium Health Levine Cancer, Charlotte, North;Carolina, USA. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39037717/ |
|---|
